Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received marketing approval in China for its innovative monoclonal antibody, tagitanlimab, aimed at treating recurrent or metastatic nasopharyngeal cancer. This approval is based on a successful phase II clinical trial demonstrating a 26.5% recovery rate and a manageable safety profile. Investors are advised to exercise caution when dealing in company securities as the commercialization success of tagitanlimab is not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.